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The main goal of this thesis was to investigate how social stimuli change behavioral, 
neurotrophic and neuroinflammatory parameters. For this purpose, three kinds of social stimuli were 
applied: I) social enrichment; II) social isolation; III) social defeat. Together, these factors are able to 
identify, to a certain extent, how the animal responds to different social cues, and how the brain is 
modulated by both beneficial and harmful social stimuli. To understand how social stimuli affect the 
behavior, neurotrophic factors, and neuroinflammatory processes, we investigated several 
parameters that together modulate – for better or worse – social behavior in animals. Different 
coping mechanisms against harmful stressors can alter these very outcomes. This chapter will 
provide an overview of how each of the investigated parameters is related to depressive behavior, 
and how these findings can be implemented or improved in future studies. 
BDNF: just another biomarker? 
BDNF has been taken into consideration as a potential biomarker of general brain function for 
almost as long as its discovery but is rarely used as a diagnostic biomarker or biomarker for 
therapeutic outcomes. Chapter 2 of this thesis provides information about how this neurotrophic 
factor is related to a variety of processes that affect the brain. In this literature review, we showed 
that there are plenty of studies showing altered concentrations of BDNF in various psychiatric and 
neurodegenerative diseases. Therefore, it is unlikely that BDNF can present itself as a diagnostic 
biomarker of one disease, but more as a biomarker of a state of disease of the brain or as a 
biomarker for the efficacy of therapeutic interventions. BDNF is activity-dependent, meaning that, 
from protein expression and production to release and binding to the TrkB receptor, it depends 
mostly on the endogenous and exogenous, beneficial and harmful, stimuli that require constant 
adapting by the organism. Harmful stimuli such as chronic stress, disease, and neuroinflammation 
usually decrease BDNF levels, while beneficial stimuli such as physical and cognitive activities and a 
good social environment enhances its production and release. 
In Chapter 3, the concept of activity-dependent expression of BDNF is used as a basis to tackle 
a very fundamental (and often disregarded) question: is what is observed in the serum related to 
what is observed in the brain? When studying BDNF, animal models show expression of this protein 
in several cognition- and disease-related brain structures (e.g.: hippocampus, frontal cortex, 
amygdala) 1,2. In humans, assessment of brain concentration of BDNF is not yet possible. Therefore, 
researchers have only observed how this protein behaves in the serum or plasma of a diverse 
population 3. However, the few animal studies trying to address the question of whether serum and 
brain BDNF levels are related more often than not were unable to reach a conclusion 4,5. In this study 
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we used two conditions that were shown to modify BDNF levels in serum (in humans) and the brain 
(in animals): age 6–8 and environment 9,10.  
Although age did not have a significant effect on BDNF levels in our study, the environment 
had an effect not only on the level of BDNF and its precursor proBDNF in the hippocampus but also 
on anxiety-like behavior, long-term memory, and synaptic plasticity. Interestingly, the effects on 
BDNF were only found in the brain and were not correlated with serum BDNF. Although translating 
animal findings to human studies is challenging, these results shed light on how BDNF behaves in the 
brain after environmental stimuli, and cast a shadow over its use as a serum biomarker of brain 
functioning. It is possible that this brain/serum discrepancy can be explained by the function of BDNF 
in each of the regions of interest. In the brain, BDNF is mainly associated with the maintenance of 
neuronal function by modulating synaptic and dendritic branching, while in the serum, BDNF may 
have a different, not yet described, function. Peripheral BDNF is produced in several tissues, but 
there is no clear indication as to what this means on a functional level. BDNF is also stored in 
platelets and it is hypothesized that upon activity, such as physical exercise 11,12, there is a release of 
platelet BDNF in the bloodstream, thus influencing, to a certain extent, peripheral BDNF 
concentration. This hypothesis can lead to two different perspectives: 1) BDNF levels in the brain of 
animals are loosely related to its levels in the serum, whereas in humans the BDNF levels in the brain 
and serum are more closely related, as suggested by the literature on serum BDNF in case-control 
studies 13–15; 2) There could be an unknown mechanism that maintains peripheral BDNF 
concentration constant, whether by regulating Bdnf gene expression and production, or by 
modulating the release of the neurotrophin in the bloodstream. Regardless, these findings question 
the feasibility of peripheral BDNF as a biomarker for brain function in humans, as it should be taken 
into account that what is observed in the serum may not reflect what is happening in the brain. 
As it is not possible to measure brain BDNF levels in living humans, the need for new 
techniques that are able to measure BDNF in vivo is imperative. PET radioligands for BDNF or tracers 
that compete with BDNF for its binding to the TrkB receptor could be a potential tool to investigate 
how this protein behaves in the brain. Small molecules that mimic BDNF and bind as agonists to the 
receptor TrkB are already on the market, and might have the requirements needed for a good 
radiotracer candidate (i.e.: strong and specific binding affinity; penetration of the blood-brain barrier; 
relatively fast clearance from non-target tissues, and systemic clearance that is compatible to tracer 
binding to its receptor). If a PET technique with such a tracer is successfully developed and can be 
applied in future studies, it will create a whole new field of opportunities to explore how BDNF can 
be (or not) used as a biomarker for brain state. 
 145 
 
Social stress: a change of paradigm? 
Continuing our focus on social stress, the next chapters of this thesis focused more on how 
negative social stimuli can affect the brain and may lead to stress-dependent depressive-like 
behavior. In addition, we attempted to modulate the stress response by applying different 
interventions and we investigated how such negative stimuli would affect depressive and anxiety 
behaviors, BDNF and neuroinflammatory markers in the brain using PET imaging 16. Depression is a 
multifaceted disorder, with many different factors contributing to its development and progression 
17. Therefore, to understand how every system affects depressive behavior is an impossible task. 
Several hypotheses have been developed to explain the biological aspects of depression. One of the 
main hypotheses is that unresolved chronic stress can trigger depressive-like behavior by 
deregulation of the HPA-axis, inducing a modification in the cortisol response (usually increasing 
cortisol concentration in the blood) and impaired negative feedback of the HPA-axis 18,19. 
Taking this paradigm into account, Chapter 4 applied both neuroendocrine and 
neuroinflammatory markers in order to better understand how stress-dependent depressive-like 
behavior is affected in animals that lack a proper HPA-axis response. In this study, we used a 
repeated social defeat protocol (RSD) as a trigger for stress-induced depressive-like behavior in 
animals previously adrenalectomized (ADX) and assessed how ADX affects short-term social behavior 
(1 day after RSD), long-term anxiety-like behavior and neuroinflammatory correlates (14 days after 
RSD). Animals submitted to ADX showed resilience against stress-dependent impairment of social 
interaction one day after RSD. This might be explained by the ablation of fight-or-flight response by 
inhibition of HPA-axis response 20,21. As anxiety- and depressive-behavior were not observed, we 
assumed a very specific effect of RSD in social behavior, possibly inducing a fear response towards 
other animals 22. By blocking HPA signaling, the fear response is also impaired, and the animal is less 
reactive to stressors.  
As corticosterone measurement is challenging in ADX animals, pharmacological interventions 
such as antagonists of glucocorticoid and mineralocorticoid receptors (GR and MR, respectively) offer 
a transient option instead of ADX to measure effects of corticosterone. Other measures for stress can 
be used to properly address how RSD affects stress response independent of the HPA-axis in vivo 
(e.g.: heart rate recording, temperature measurement) and ex vivo (glucocorticoid and 
mineralocorticoid receptors, adrenocorticotropic hormone (ACTH) and corticotropin-releasing 
hormone (CRH)). Lastly, behavioral measurements that are more related with fear behavior (i.e.: 
passive-avoidance test; unconditional fear stimulus with predator odor – or with the smell of a 
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resident from the RSD protocol) might be an interesting feature to confirm if the fear response is 
inhibited in ADX animals submitted to RSD.  
In our next study, we decided to modify how the RSD protocol was performed, and change the 
time between the last RSD trial and the [11C]PBR-28 scan. In this study, we addressed if treatment 
with antidepressant and anti-inflammatory compound harmine 23–25 would be able to modify the 
(possible) inflammatory response, behavioral abnormalities and changes in BDNF concentration in 
the brain of defeated animals. In chapter 4 we applied a barrier in the center of the cage separating 
intruder and resident, while in Chapter 5 we placed the intruder in a wire mesh cage, thus providing 
a more intimidating environment for the intruder, while still avoiding physical contact between 
resident and intruder 26. These changes seem to have had a significant short-term effect on the 
behavior of the intruder, such as more anxiety-like behavior in the open field test and more 
depressive-like behavior in the sucrose preference test when compared with non-defeated animals. 
Physiologically, the weight of socially defeated animals also decreased during the RSD protocol, an 
indication of a state of anhedonia, further confirmed by a lower preference for water with sucrose in 
the sucrose preference test (SPT). When the same tests were applied at a later time point, however, 
no effect on the anxiety and depressive-like behavior of the animals submitted to RSD was observed 
anymore, indicating that the effect of RSD was transient, not lasting until the end of the study 
protocol. Additionally, we analyzed neuroinflammation by [11C]PBR-28 eleven days after the last RSD 
trial, and the brain BDNF concentration post-mortem, and no difference between RSD and control 
were found for these molecular parameters. 
Interestingly, RSD has shown a strong data variance in the sucrose preference test one day 
after RSD. In this regard, it is likely that some animals have shown a tendency to be more sensitive 
against the stressful stimuli, thus presenting higher anhedonia when compared to the other groups. 
It is possible that there is a high inter-individual variance in this regard, and future observations are 
advisable to take this variation into account. Thus, further studies on the matter should consider 
dividing the animals submitted to RSD into stress-susceptible and resistant subgroups. Once more, 
the findings of this chapter are related to the ones from chapter 4, as a short- but not long-term 
effect was observed in the behavioral outcomes for RSD, once again demonstrating that RSD was not 
as strong as we expected, and its effects disappeared within one week. However, in chapter 5, 
harmine was able to induce a significant long-term change in the locomotion of the animal, with a 
lower distance traveled when compared with vehicle animals. We hypothesize that this might be due 
to the tremorgenic effect of the drug 27, causing a lingering decrease of general locomotion, although 
there are no other studies showing similar effects. After every injection the animals showed transient 
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tremors, receding after one hour. However, it is possible that other mechanisms might be playing a 
role that we failed to assess visually, and therefore might be hampering the locomotion of the animal 
in a long-term fashion. With the lack of a proper RSD-dependent depressive-like behavior, it is 
difficult to ascertain the feasibility of harmine as an antidepressant and anti-inflammatory 
compound. However, the effects on locomotion and weight might point towards a negative effect of 
harmine when coping with stress, which might be something to consider in future studies using this 
compound. 
Timing matters: neuroinflammatory processes in social stress 
The results found in chapters 4 and 5 regarding neuroinflammation were, to a certain extent, 
surprising, as we hypothesized that the effect of RSD would be stronger than what was observed. We 
expected a long-term modification in the brain circuitry associated with depressive-like behavior and 
the neuroinflammatory theory of depression. If the inflammatory process is impaired, or the stressor 
is repeated over a period of time, it might cause a chronic inflammatory process in the organism, 
leading to long-term damage to neurons and, consequently, neuronal death. 
 In this regard, two possibilities arise for the failure to neuroinflammation in our studies: the 
chronic stress was not strong enough to impose an inflammatory response from microglia; or the 
timing of PET scan was incorrect, as the microglia may have been less activated than expected, and 
consequently the inflammatory response was already in its final stage (i.e.: resolution) two weeks 
after the last social stress trial 28. However, the results of our study should be interpreted with care, 
as there was a very large variance in the [11C]PBR28 PET signal in animals submitted to RSD in both 
studies. This might point towards the presence of stress-sensitive and stress-resilient sub-
populations in our study. Mimicking human diseases in animal models in order to better understand 
the pathophysiology is one of the most difficult challenges of preclinical research. In this respect, 
depression is a particular challenge in the field of mood and psychiatric disorders. The multimodal 
pattern of MDD, along with the high variability of symptoms, makes it virtually impossible to study all 
aspects of the disease in one animal model only 29. Therefore, researchers investigating cognition in a 
preclinical setting tend to “bestialize” human behaviors 30, assuming that what is considered 
threatening or beneficial in humans can be assumed to have the same impact on animals. This might 
not be the case in the RSD paradigm used 30,31. Several studies have shown an effect of RSD on 
behavioral outcomes in the short-term (reviewed by Hollis et al. 32), but the effects of RSD in the 
long-term are not very well studied. Thus, some options to improve the stress response to develop 
depressive-like symptoms include: 1) the use of different stressors (one such stressor could be the 
previously used long-term social isolation, as it was shown as a promoter of anxiety-like behavior in 
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animals); 2) increase its length, thus increasing the contact with the stressor; 3) animals genetically 
susceptible to develop depression could decrease the inter-individual variability at the cost of 
possibly skewing the results towards one side of the population, disregarding resilient animals; 4) 
increasing the number of animals in order to take inter-individual variability into consideration in the 
study. All these options might be needed in order to induce reliable changes in animals for 
development of depressive behavior. 
Another point to be taken into consideration is the neuroinflammatory marker that was used 
in our studies. TSPO as a biomarker for inflammation has been used for a long time in the molecular 
imaging field, showing promising results for neurodegenerative diseases, where inflammatory 
processes are usually more pronounced 33,34. In psychiatric disorders, however, there is still a debate 
on how reliable TSPO radiotracers can be for neuroinflammatory surveillance and assessment of 
microglial activation. Consequently, the use of TSPO as an imaging biomarker for neuroinflammation 
in human and animal studies is under scrutiny 35,36. For instance, Setiawan and colleagues found in a 
very large MDD cohort that the volume of distribution (Vt) of the TSPO tracer [
18F]-FEPPA in the 
prefrontal cortex, anterior cingulate cortex, and insular cortex was associated with progression of 
untreated depressive disorder. However, the same investigators found that this effect is significantly 
more pronounced in subjects with a long-term, untreated MDD (over 10 years), whereas subjects 
with shorter-term progression of depression (less than 5 years) show no difference in tracer uptake 
when compared with control subjects 37. Other studies with [11C]PBR28 in humans have shown a 
positive association between increased neuroinflammation in the anterior cingulate cortex and 
increased progression of perceived depression 38,39. These results show that, while progression of 
disease is associated with an increase of TSPO uptake in specific MDD-related brain areas, this effect 
seems to be observed more in a late-stage of disease (i.e.: chronic MDD), when the brain circuitry is 
more impaired and damage-associated neuroinflammation is more pronounced.  
However, the point where the “allostatic breakdown” of a subject leads to the activation of the 
neuroinflammatory cascade is not clear yet. It is difficult to draw a conclusion without knowledge of 
the mechanisms, and inter-individual differences make the challenge even harder. There is a need for 
novel techniques that show increased sensitivity and specificity in assessing slight neuroinflammatory 
patterns, or even pro/anti-inflammatory patterns in vivo. But in the meantime, studies focusing on 
PET imaging of TSPO should take advantage of the in vivo data collection and try to assess what is the 
best time point to get the best result out of it, and from there on, focus on development and 
treatment of inflammation as a part of depressive-like behavior. 
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To the victor goes the spoils: how dopaminergic neurons react to winning? 
Dopamine is a neurotransmitter involved in the functioning of the limbic system, mainly 
associated with reward 40,41. In humans, aggression has also been associated with altered D2R 
expression 42–44, although there are also reports stating otherwise 45. In Chapter 6 we took advantage 
of the social defeat paradigm to study the behavior of the animals that were trained to be the 
aggressors (i.e.: residents). In this chapter, we compared two different cohorts of aggressors: one 
cohort of animals that were used in the studies described in chapters 4 and 5 of this thesis, and a 
cohort from another independent study using a similar protocol 46. In both cohorts, [11C]-raclopride 
PET imaging was applied to assess D2 receptor availability and compared with non-aggressive control 
animals. As the timing between the last RSD trial and the [11C]-raclopride PET scan was different 
between cohorts, the groups were divided between controls (no aggression), cohort 1 (animals used 
in chapters 4,5) and cohort 2 (animals from another study). There was a significant difference in the 
behavior of animals, with cohort 2 showing a characteristic decrease in the attack latency over time 
when compared with cohort 1 and controls. This group also showed a difference in the dorsal 
striatum D2 receptor availability, with a two-fold increase in the binding potential of [
11C]-raclopride 
when compared with the other groups.  
Striatal D2 receptors in this region are mainly associated with modulation of medium spiny 
neurons – the main producers of γ-aminobutyric acid (GABA). While the nucleus accumbens (ventral 
striatum) drives changes in motivation (i.e.: hedonic state and reward circuitry 47,48), the dorsal 
striatum plays a role in habit formation 49,50. As binding potential is increased, it means more 
availability of D2 receptors, which could indicate that less dopamine is bound to this receptor, 
51 or 
overexpression of the receptor. If the decrease in signal is due to a reduced release of dopamine, this 
might lead to a decreased GABAergic signaling and a consequent lack of inhibition of several limbic 
system-associated brain regions 51. It is possible that these disinhibited regions affect the brain in a 
way that the animals become increasingly more aggressive over time. In the other cohort, the 
animals may show habituation towards the stressor, explaining the significantly higher attack latency. 
However, it is difficult to draw further conclusions about innate differences between the cohorts.  
As this study was only able to observe D2 availability after RSD, studies that focus on the 
development of aggressive behavior, such as the one described in this thesis, would greatly benefit 
from a baseline PET scan in order to show how D2 receptors are presented before introducing the 
animal to the RSD protocol. This way, it would be possible to depict the entire scenario of aggression 
development. Another interesting topic to observe is the behavior of dopamine D1 receptor 
availability, as it is already shown that D1 and D2 show distinct functions in the signaling of GABAergic 
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neurons in the dorsoventral striatum. Lastly, other brain structures are reportedly associated with 
aggressive behavior and can, unfortunately, not be assessed by [11C]-raclopride PET (e.g.: 
orbitofrontal cortex 52, hypothalamic structures 53, habenula 54). All these structures form a complex 
and intertwined system for modulation of aggressive behavior, making the study of aggressive 
behavior a very challenging one. Dopamine is one of many players responsible for this behavior, and 
future studies should take that into account when designing their studies. 
Concluding remarks – It is a matter of time 
Depression is a major future concern, which will lead to worldwide healthcare and workforce 
issues. Except in regions of extremely stressful conditions (e.g.: famine, poverty, warzones), modern-
day chronic, social stress, has never been so high, which is a major concern for the onset and 
progression of depression. This thesis has shown that the effect of subchronic and chronic social 
manipulation – whether positive or negative – affects several brain functions, especially in the short-
term. However, when long-term changes were assessed, the parameters analyzed were already 
normalized. Chronic, positive social stimulation such as environmental enrichment improved several 
parameters associated with neuronal survival and plasticity and synaptic functioning. On the other 
hand, chronic social stress, such as the social isolation protocol has shown a tendency to impair these 
parameters, showing an expected duality between positive and negative stimulation. Interestingly, 
long protocols such as social isolation and social enrichment were able to induce the modifications 
needed to assess how BDNF behaves after social stimulation, but there was a discrepancy between 
what was found in the brain of these animals and what was observed in the serum. Taking all rodent-
to-human translation issues into consideration, this lack of interaction between BDNF in the brain 
and serum will fuel an exciting discussion and should be taken into consideration for future research 
involving this neurotrophic factor as a relevant peripheral biomarker for brain functioning. For this, 
PET imaging of TrkB receptors, or BDNF itself, might help us to better understand the behavior of this 
neurotrophin in vivo. 
in our studies, subchronic stressors, such as social defeat, induced a short-term but not a long-
term effect on the animals’ behavior, with no changes in neuroinflammatory and neurotrophic 
parameters. TSPO imaging showed no effect of RSD in the animals, suggesting that these animals had 
no neuroinflammation at the point of analysis, and together with the lack of difference in the 
depressive-like behavioral outcomes and BDNF concentration at the same time point, we can 
hypothesize that the acute depressive-like behavior shown shortly after RSD was transient, and had 
normalized within two weeks. It would be interesting to study if, after two weeks, the negative and 
positive effects of isolation and enrichment, respectively, would still be visible.  
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Assessment of the other side of social stress yielded some interesting results. [11C]raclopride 
PET showed a significant change in aggressor animals of one cohort when compared to another 
aggressive cohort and control animals that did not show any aggressive behavior. This was also 
observed in the scaling of aggressive behavior, with animals showing higher striatal binding potential 
also having a lower attack latency. However, the data collected was from animals that underwent 
several trials of RSD, thus it is not possible to confirm that changes in aggressive behavior were 
caused by innate lack of dopaminergic binding to D2 receptors, and other studies using baseline 
measurements should be done in order to have a reliable starting point and avoiding between-group 
differences at baseline. 
As the prevalence of mood disorders will increase in the coming decades, the need for new 
and improved methods to diagnose and treat these conditions are of major importance for 
psychiatrists and neurologists alike, and understanding the mechanisms that affect – or are affected 
by – such disorders are the first step of this challenge. As the most commonly diagnosed psychiatric 
disorder, depression is the main example of what we are dealing with a multifaceted disease with 
many starting points and comorbidities that, in the end, severely affect both individuals and their 
peers. In order to treat the disorder, first it is needed to understand how these processes are 
involved in the development of MDD. Only then, it will be possible to strive for individual treatment 
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